

Francesco Merli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2864209/francesco-merli-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

5,304
citations

39
h-index

71
g-index

117
ext. papers

6,205
ext. citations

4.3
avg, IF

4.53
L-index

#	Paper	IF	Citations
112	Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls.. <i>Current Oncology</i> , 2022 , 29, 956-968	2.8	1
111	KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells. <i>Oncology Reports</i> , 2022 , 47,	3.5	1
110	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1214-1222	2.2	21
109	Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 , 12, 1042-1055	10.3	3
108	Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach. <i>Cancers</i> , 2021 , 13,	6.6	10
107	Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 192, 1011-1014	4.5	2
106	Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2021 , 39, 205-214	1.3	1
105	Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. <i>Annals of Hematology</i> , 2021 , 100, 2547-2556	3	0
104	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. <i>Ocular Immunology and Inflammation</i> , 2021 , 1-9	2.8	0
103	EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2). <i>Cancers</i> , 2021 , 13,	6.6	9
102	EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1). <i>Cancers</i> , 2021 , 13,	6.6	11
101	Caregivers of Patients with Hematological Malignancies within Home Care: A Phenomenological Study. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	3
100	The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK anaplastic large cell lymphoma by regulating the DNA helicase HELLS. <i>Leukemia</i> , 2020 , 34, 2964-2980	10.7	6
99	Hodgkin's lymphoma: post- autologous transplantation consolidation therapy. <i>Acta Biomedica</i> , 2020 , 91, 23-29	3.2	3
98	A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. <i>Clinical Cancer Research</i> , 2020 , 26, 373-383	12.9	3
97	Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2020 , 4, 136-140	7.8	12
96	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019 , 60, 2890-2898	1.9	5

95	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2019 , 394, 2271-2281	4.0	85
94	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. <i>Bone Marrow Transplantation</i> , 2018 , 53, 461-473	4.4	17
93	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018 , 36, 68-75	1.3	20
92	Transplant results in adults with Fanconi anaemia. <i>British Journal of Haematology</i> , 2018 , 180, 100-109	4.5	16
91	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the. <i>Haematologica</i> , 2018 , 103, 1345-1350	6.6	26
90	Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit. <i>British Journal of Haematology</i> , 2018 , 183, 819-822	4.5	5
89	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 689-696	2.2	81
88	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). <i>Journal of Clinical Oncology</i> , 2018 , 36, 2593-2602	2.2	40
87	Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. <i>Lancet Haematology,the</i> , 2017 , 4, e272-e282	14.6	74
86	Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2017 , 57, 89-96	2.7	13
85	Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1786-1794	2.2	264
84	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1076-1088	21.7	72
83	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017 , 92, 37-41	7.1	53
82	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017 , 8, 79073-79086	3.3	38
81	Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. <i>Haematologica</i> , 2016 , 101, e139-41	6.6	10
80	Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016 , 38, 247-51		1
79	Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2016 , 172, 879-88	4.5	25
78	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016 , 57, 2375-81	1.9	5

77	Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3293-9	2.2	66
76	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2677-80	1.9	1
75	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1175-81	2.2	74
74	Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. <i>British Journal of Radiology</i> , 2016 , 89, 20150983	3.4	10
73	Reply to T.P. Vassilakopoulos et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3585-3586	2.2	0
72	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016 , 3, e467-e479	14.6	44
71	Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 1077-1083	4	27
70	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015 , 100, 517-24	6.6	4
69	Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: experience with 27 patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 404-8	2	17
68	Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3281-7	1.9	19
67	The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015 , 90, 499-503	7.1	38
66	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015 , 29, 1344-9	10.7	48
65	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015 , 126, 950-6	2.2	111
64	Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future. <i>Current Oncology Reports</i> , 2015 , 17, 31	6.3	3
63	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015 , 26, 185-192	10.3	48
62	Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1113-22	8.8	114
61	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014 , 25, 1404-1410	10.3	114
60	Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. <i>Lancet Oncology</i> , 2014 , 15, 343-52	21.7	82

59	Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 370-5	4	39
58	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014 , 25, 442-7	10.3	51
57	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014 , 55, 38-43	1.9	54
56	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013 , 88, 581-8	7.1	46
55	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1506-13	2.2	193
54	Resveratrol-mediated apoptosis of hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation. <i>International Journal of Cancer</i> , 2013 , 132, 1013-21	7.5	71
53	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013 , 24, 2108-12	10.3	104
52	Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013 , 5, e2013037	3.2	7
51	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013 , 54, 53-7	1.9	36
50	Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. <i>Hematological Oncology</i> , 2013 , 31, 151-5	1.3	7
49	Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patients. <i>PLoS ONE</i> , 2013 , 8, e74326	3.7	47
48	Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. <i>Leukemia and Lymphoma</i> , 2012 , 53, 406-10	1.9	3
47	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012 , 53, 581-8	1.9	56
46	Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. <i>Hematological Oncology</i> , 2012 , 30, 194-9 ^{1.3}		12
45	Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. <i>Cancer</i> , 2012 , 118, 3954-61 ^{6.4}		18
44	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. <i>Annals of Hematology</i> , 2012 , 91, 931-9	3	56
43	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012 , 156, 346-53	4.5	101
42	Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters. <i>Oncology Reports</i> , 2012 , 28, 815-20	3.5	7

41	Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 396-402	2	10
40	Increase in clusterin forms part of the stress response in Hodgkin's lymphoma. <i>International Journal of Oncology</i> , 2011 , 38, 677-84	4.4	1
39	Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Annals of Hematology</i> , 2011 , 90, 323-30	3	10
38	Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1689-96	1.9	4
37	First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2766-72	2.2	135
36	The incidence of <i>Pneumocystis jirovecii</i> pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate <i>Pneumocystis jirovecii</i> pneumonia prophylaxis. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1418-26	1.9	4
35	Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4227-33	2.2	38
34	Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1867-72	1.9	37
33	Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. <i>Leukemia and Lymphoma</i> , 2010 , 51, 422-9	1.9	2
32	ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 805-11	2.2	206
31	Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4555-62	2.2	483
30	Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 138-44		8
29	The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 425-9		3
28	Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. <i>Oncology Reports</i> , 2009 , 21, 1029-35	3.5	5
27	Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Update of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324).. <i>Blood</i> , 2009 , 114, 2686-2686	2.2	1
26	Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. <i>Cancer</i> , 2007 , 109, 2077-82	6.4	46
25	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. <i>Cancer</i> , 2007 , 110, 121-8	6.4	39
24	Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. <i>Annals of Hematology</i> , 2007 , 86, 897-903	3	86

23	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3746-52	2.2	667
22	Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. <i>Haematologica</i> , 2007 , 92, 1482-8	6.6	30
21	Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 367-73	1.9	19
20	Non-Pegylated Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study. <i>Blood</i> , 2007 , 110, 1293-1293	2.2	3
19	R-CHOP vs R-MiniCEOP in Elderly Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) Prospectively Selected by a Multidimensional Evaluation Scale: Preliminary Results of a Randomized Study Performed by Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2007 , 110, 3429-3429	2.2	1
18	The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. <i>European Journal of Haematology</i> , 2006 , 76, 217-29	3.8	7
17	The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL). <i>Annals of Oncology</i> , 2006 , 17, 676-82	10.3	3
16	Splenic marginal zone lymphoma: a prognostic model for clinical use. <i>Blood</i> , 2006 , 107, 4643-9	2.2	177
15	The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Bone Marrow Transplantation</i> , 2006 , 37, 283-8	4.4	18
14	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. <i>Haematologica</i> , 2006 , 91, 475-81	6.6	190
13	ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9198-207	2.2	144
12	The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. <i>Cancer</i> , 2004 , 101, 1824-34	6.4	37
11	Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1459-65	2.2	20
10	Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi. <i>Cancer</i> , 2003 , 98, 2393-401	6.4	24
9	The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1911-7	1.9	19
8	Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1933-8	1.9	7
7	Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). <i>Leukemia and Lymphoma</i> , 2002 , 43, 1795-801	1.9	5
6	Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1388-94	2.2	48

5	Erythema nodosum and Hodgkin's disease. <i>Clinical and Experimental Dermatology</i> , 2001 , 26, 408-11	1.8	17
4	Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. <i>Cancer</i> , 2001 , 91, 1467-78	6.4	42
3	Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. <i>Acta Haematologica</i> , 1995 , 93, 31-5	2.7	22
2	ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). <i>Leukemia and Lymphoma</i> , 1995 , 17, 313-20	1.9	14
1	T-cell receptor genes expression in B-cell leukaemias. <i>British Journal of Haematology</i> , 1989 , 72, 343-9	4.5	6